作为GSK3α抑制剂的新型异环胺衍生物
1Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
ACS medicinal chemistry letters
|May 14, 2025
概括
新型皮里米丁衍生物选择性地抑制糖原合成酶激酶3α (GSK3α),显示出对结直肠癌治疗的希望. 这些化合物在临床前小鼠模型中显示出有效性.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 糖原合成酶激酶3α (GSK3α) 涉及到各种细胞过程,包括癌症的进展.
- 选择性抑制GSK3α超过GSK3β是一个治疗挑战.
- heterocyclic pyrimidine支架正在被探索,因为它们在药物发现中的潜力.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Parkinson's Disease: Treatment
162
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
162


